5-PAHSA

• Product Name Alternative:

  trans-PX-102, (-)-PX-102 (trans isomer); (-)-PX-104, PX-111, ABR-215757-d5-1; ABR 25757-d5-1

• UNSPSC Description:

  5-PAHSA increases insulin sensitivity, and has orally active anti-inflammatory and neuroprotective effects in mice HFD-induced diabetes mice. 5-PAHSA can be used for research of neurological dysfunction in diabetics[1][2][3].

• Target Antigen:

  Endogenous Metabolite

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Field of Research:

  Metabolic Disease; Inflammation/Immunology; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/5-pahsa.html

• Purity:

  98.08

• Solubility:

  DMSO : 16.67 mg/mL (ultrasonic;warming;heat to 80°C)

• Smiles:

  OC(CCCC(CCCCCCCCCCCCC)OC(CCCCCCCCCCCCCCC)=O)=O

• Molecular Weight:

  538.89

• References & Citations:

  [1]Wang JT, et al. A novel palmitic acid hydroxy stearic acid (5-PAHSA) plays a neuroprotective role by inhibiting phosphorylation of the m-TOR-ULK1 pathway and regulating autophagy. CNS Neurosci Ther. 2021 Apr;27(4):484-496.|[2]Paluchova V, et al. Lipokine 5-PAHSA Is Regulated by Adipose Triglyceride Lipase and Primes Adipocytes for De Novo Lipogenesis in Mice. Diabetes. 2020 Mar;69(3):300-312. |[3]Wang YM, et al. High Glucose Concentration Impairs 5-PAHSA Activity by Inhibiting AMP-Activated Protein Kinase Activation and Promoting Nuclear Factor-Kappa-B-Mediated Inflammation. Front Pharmacol. 2019 Jan 7;9:1491.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1481636-41-2